Suppr超能文献

比利时癌症患者的营养不良患病率:ONCOCARE研究。

Malnutrition prevalence in cancer patients in Belgium: The ONCOCARE study.

作者信息

Rasschaert Marika, Vandecandelaere Pieter, Marechal Stéphanie, D'hondt Randal, Vulsteke Christof, Mailleux Marie, De Roock Wendy, Van Erps Joanna, Himpe Ulrike, De Man Marc, Mertens Geertrui, Ysebaert Dirk

机构信息

Antwerp University Hospital, Antwerp, Belgium.

AZ Delta, Roeselare, Belgium.

出版信息

Support Care Cancer. 2024 Jan 27;32(2):135. doi: 10.1007/s00520-024-08324-6.

Abstract

RATIONALE

Unintentional weight loss and malnutrition are common among cancer patients. Malnutrition has been associated with impaired health-related quality of life, less well-tolerated chemotherapy regimens and shorter life duration. In Belgium there is a lack of epidemiological data on malnutrition in oncology patients at advanced stages of the disease.

METHODS

Malnutrition assessment data was collected through a prospective, observational study in 328 patients who started a neoadjuvant anticancer therapy regimen or who started 1st, 2nd or 3rd line anticancer therapy for a metastatic cancer via 3 visits according to regular clinical practice (baseline visit (BV) maximum 4 weeks before start therapy, 1st Follow up visit (FUV1) ± 6 weeks after start therapy, FUV2 ± 4 months after start therapy). Malnutrition screening was evaluated using the Nutritional Risk Screening score 2002 (NRS-2002)and the diagnosis of malnutrition by the GLIM criteria. In addition, SARC-F questionnaire and Fearon criteria were used respectively to screen for sarcopenia and cachexia.

RESULTS

Prevalence of malnutrition risk at BV was high: 54.5% of the patients had a NRS ≥ 3 (NRS 2002) and increased during the study period (FUV1: 73.2%, FUV2: 70.1%). Prevalence of malnutrition based on physician subjective assessment (PSA) remained stable over the study period but was much lower compared to NRS results (14.0%-16.5%). At BV, only 10% of the patients got a nutrition plan and 43.9% received ≤ 70% of nutritional needs, percentage increased during FU period (FUV1: 68.4%, FUV2: 67.6%). Prevalence of sarcopenia and cachexia were respectively 12.4% and 38.1% at BV and without significant variation during the study period, but higher than assessed by PSA (11.6% and 6.7% respectively). Figures were also higher compared to PSA. There were modifications in cancer treatment at FUV1 (25.2%) and at FUV2 (50.8%). The main reasons for these modifications at FUV1 were adverse events and tolerability. Patient reported daily questionnaires of food intake showed early nutritional deficits, preceding clinical signs of malnutrition, and therefore can be very useful in the ambulatory setting.

CONCLUSIONS

Prevalence of malnutrition and cachexia was high in advanced cancer patients and underestimated by physician assessment. Earlier and rigorous detection of nutritional deficit and adjusted nutritional intake could lead to improved clinical outcomes in cancer patients. Reporting of daily caloric intake by patients was also very helpful with regards to nutritional assessment.

摘要

理论依据

非故意体重减轻和营养不良在癌症患者中很常见。营养不良与健康相关生活质量受损、化疗方案耐受性降低以及生存期缩短有关。在比利时,缺乏关于处于疾病晚期的肿瘤患者营养不良的流行病学数据。

方法

通过一项前瞻性观察性研究收集营养不良评估数据,研究对象为328例开始新辅助抗癌治疗方案或开始针对转移性癌症进行一线、二线或三线抗癌治疗的患者,按照常规临床实践进行3次访视(基线访视(BV)在开始治疗前最多4周,第一次随访访视(FUV1)在开始治疗后±6周,FUV2在开始治疗后±4个月)。使用2002年营养风险筛查评分(NRS - 2002)评估营养不良筛查情况,并根据GLIM标准诊断营养不良。此外,分别使用SARC - F问卷和费伦标准筛查肌肉减少症和恶病质。

结果

基线访视时营养不良风险的患病率很高:54.5%的患者NRS≥3(NRS 2002),且在研究期间有所增加(FUV1:73.2%,FUV2:70.1%)。基于医生主观评估(PSA)的营养不良患病率在研究期间保持稳定,但与NRS结果相比要低得多(14.0% - 16.5%)。在基线访视时,只有10%的患者制定了营养计划,43.9%的患者摄入的营养量≤营养需求的70%,该百分比在随访期间有所增加(FUV1:68.4%,FUV2:67.6%)。基线访视时肌肉减少症和恶病质的患病率分别为12.4%和38.1%,在研究期间无显著变化,但高于PSA评估的结果(分别为11.6%和6.7%)。这些数据也高于PSA评估的数据。在FUV1(25.2%)和FUV2(50.8%)时癌症治疗有调整。FUV1时这些调整的主要原因是不良事件和耐受性。患者报告的每日食物摄入量问卷显示,在出现营养不良临床体征之前就存在早期营养缺乏,因此在门诊环境中可能非常有用。

结论

晚期癌症患者中营养不良和恶病质的患病率很高,且被医生评估低估。更早且严格地检测营养缺乏并调整营养摄入量可能会改善癌症患者的临床结局。患者报告每日热量摄入量对营养评估也非常有帮助。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验